CU20110219A7 - Composiciones y métodos para administración de vacunas contra virus del dengue - Google Patents

Composiciones y métodos para administración de vacunas contra virus del dengue

Info

Publication number
CU20110219A7
CU20110219A7 CU20110219A CU20110219A CU20110219A7 CU 20110219 A7 CU20110219 A7 CU 20110219A7 CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A7 CU20110219 A7 CU 20110219A7
Authority
CU
Cuba
Prior art keywords
compositions
den
methods
intradermal
administration
Prior art date
Application number
CU20110219A
Other languages
English (en)
Spanish (es)
Inventor
Joseph N Brewoo
Charalambos D Partidos
Jorge E Osorio
Dan T Stinchcomb
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110219(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of CU20110219A7 publication Critical patent/CU20110219A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CU20110219A 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue CU20110219A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01

Publications (1)

Publication Number Publication Date
CU20110219A7 true CU20110219A7 (es) 2012-06-21

Family

ID=43220488

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110219A CU20110219A7 (es) 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue

Country Status (17)

Country Link
US (2) US9211323B2 (https=)
EP (1) EP2438198A4 (https=)
JP (2) JP5848243B2 (https=)
KR (1) KR101876304B1 (https=)
CN (2) CN102449172A (https=)
AU (3) AU2010256845B2 (https=)
CA (1) CA2763944A1 (https=)
CL (1) CL2011003043A1 (https=)
CO (1) CO6470882A2 (https=)
CU (1) CU20110219A7 (https=)
IL (2) IL216706A0 (https=)
MX (1) MX343172B (https=)
MY (1) MY184428A (https=)
NZ (2) NZ597000A (https=)
PH (1) PH12016502431A1 (https=)
SG (1) SG176299A1 (https=)
WO (1) WO2010141386A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US11007261B2 (en) 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231570T2 (de) * 1991-09-19 2001-06-21 Us Of America Represented By D Chimäre und/oder wachstumgehemmte Flaviviren
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
US20080193477A1 (en) 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
DK2589602T3 (en) * 2006-08-15 2016-07-25 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of dengue virus vaccine components
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus

Also Published As

Publication number Publication date
AU2016277660A1 (en) 2017-01-12
CL2011003043A1 (es) 2012-07-20
US10010600B2 (en) 2018-07-03
CN102449172A (zh) 2012-05-09
MY184428A (en) 2021-04-01
CA2763944A1 (en) 2010-12-09
KR101876304B1 (ko) 2018-07-10
JP5848243B2 (ja) 2016-01-27
JP2012528794A (ja) 2012-11-15
JP2016033151A (ja) 2016-03-10
WO2010141386A1 (en) 2010-12-09
IL216706A0 (en) 2012-02-29
PH12016502431A1 (en) 2019-02-11
CN107913406A (zh) 2018-04-17
KR20120027396A (ko) 2012-03-21
AU2010256845B2 (en) 2016-09-22
US20100303860A1 (en) 2010-12-02
US20160129102A1 (en) 2016-05-12
NZ618158A (en) 2015-05-29
US9211323B2 (en) 2015-12-15
AU2010256845A1 (en) 2011-12-22
NZ597000A (en) 2014-07-25
MX343172B (es) 2016-10-26
EP2438198A4 (en) 2014-05-14
MX2011012807A (es) 2012-01-30
AU2019200212A1 (en) 2019-01-31
CO6470882A2 (es) 2012-06-29
EP2438198A1 (en) 2012-04-11
IL243204A0 (en) 2016-02-29
SG176299A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
EP2448410A4 (en) TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
MX374519B (es) Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
UY32457A (es) Vacuna del virus del dengue inactivado
ECSP14013315A (es) Inhibidores de aplicación viral
PE20140646A1 (es) Vacuna de virus de dengue inactivado
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
BR112015001313A2 (pt) composições de vacina
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
MX383330B (es) Particula tipo virus de flavivirus.
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CO2017005830A2 (es) Composiciones de vacuna para el virus del dengue
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
AR082057A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i)
TH91621B (th) วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก
TH137870A (th) องค์ประกอบและวิธีการสำหรับการให้ของวัคซีนต่อต้านไวรัสเดงกี่ (dengue virus)
NI201400025A (es) Inhibidores de aplicación viral